Статья
Клиническое значение серийного определения активности современных биомаркеров у больных после декомпенсации сердечной недостаточности: роль sST2 и NT-proBNP при длительном наблюдении
Цель. Мониторирование концентрации современных биомаркеров для оценки эффективности длительного лечения больных после острой декомпенсации СН (ОДСН).Материалы и методы. В исследование было включено 100 пациентов с тяжелой декомпенсированной ХСН III–IV ФК и ФВ ЛЖ
1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. Journal of the American College of Cardiology. 2013;61(12):1259-67. DOI: 10.1016/j.jacc.2012.12.038
2. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2013;15(7):808-17. DOI: 10.1093/eurjhf/hft050
3. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission. Circulation: Cardiovascular Quality and Outcomes. 2009;2(5):407-13. DOI: 10.1161/CIRCOUTCOMES.109.883256
4. Harjola V-P, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure. 2010;12(3):239-48. DOI: 10.1093/eurjhf/hfq002
5. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J et al. EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2010;12(10):1076-84. DOI: 10.1093/eurjhf/hfq154
6. Скворцов А. А., Протасов В. Н., Нарусов О. Ю., Кошкина Д. Е., Насонова С. Н., Масенко В. П. и др. Определение концентрации растворимого рецептора подавления туморогенности 2-го типа расширяет возможности в стратификации риска больных после перенесенной декомпенсации хронической сердечной недостаточности. Кардиология. 2017;57(1):48-58. DOI: 10.18565/cardio.2017.1.48-58
7. Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology. 2011;58(18):1881-9. DOI: 10.1016/j.jacc.2011.03.072
8. Скворцов А. А., Кошкина Д. Е., Нарусов О. Ю., Протасов В. Н., Масенко В. П., Терещенко С. Н. Терапия под контролем NT-концевого предшественника натрийуретического пептида у больных хронической сердечной недостаточностью из группы высокого риска после декомпенсации. Основные результаты. Кардиология. 2016;56(7):25-38. DOI: 10.18565/cardio.2016.7.25-38
9. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011;4(2):180-7. DOI: 10.1161/CIRCHEARTFAILURE.110.958223
10. Bayes-Genis A, de Antonio M, Vila J, Penafiel J, Galan A, Barallat J et al. Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. Journal of the American College of Cardiology. 2014;63(2):158-66. DOI: 10.1016/j.jacc.2013.07.087
11. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgentha-ler NG et al. Comparative Evaluation of B-Type Natriuretic Peptide, Mid-Regional Pro-A-type Natriuretic Peptide, Mid-Regional Pro-Adrenomedullin, and Copeptin to Predict 1-Year Mortality in Patients with Acute Destabilized Heart Failure. Journal of Cardiac Failure. 2007;13(1):42-9. DOI: 10.1016/j.cardfail.2006.09.004
12. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP et al. Plasma Copeptin Levels and Prediction of Outcome in Heart Failure Outpatients: Relation to Hyponatremia and Loop Diuretic Doses. Journal of Cardiac Failure. 2012;18(5):351-8. DOI: 10.1016/j.card-fail.2012.01.019
13. O’Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang L-M, Solomon SD et al. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients with Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation: Heart Failure. 2018;11(5). DOI: 10.1161/CIRCHEARTFAILURE.117.004446
14. Van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG et al. Prognostic Value of Serial ST2 Measurements in Patients with Acute Heart Failure. Journal of the American College of Cardiology. 2017;70(19):2378-88. DOI: 10.1016/j.jacc.2017.09.026
15. Gaggin HK, SzymonifkaJ, Bhardwaj A, Belcher A, De Berardinis B, Moti-wala S et al. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients with Chronic Heart Failure. JACC: Heart Failure. 2014;2(1):65-72. DOI: 10.1016/j.jchf.2013.10.005
16. Скворцов А. А., Протасов В. Н., Нарусов О. Ю., Кошкина Д. Е., Осмоловская Ю. Ф., Кузнецова Т. В. и др. Растворимый рецептор подавления туморогенности 2-го типа против копептина: прямое сравнение значения определения новых биомаркеров для прогноза у больных с декомпенсированной сердечной недостаточностью. Кардиология. 2017;17(9):20-33. DOI: 10.18087/cardio.2017.9.10028
17. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594-600. DOI: 10.1161/01.CIR.0000112582.16683.EA
18. Januzzi JL. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. European Heart Journal. 2005;27(3):330-7. DOI: 10.1093/eurheartj/ehi631
19. Wu AHB, Smith A, Wieczorek S, Mather JF, Duncan B, White CM et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. The American Journal of Cardiology. 2003;92(5):628-31. PMID: 12943894
20. Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. European Journal of Heart Failure. 2013;15(8):859-67. DOI: 10.1093/eurjhf/hft048
21. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R et al. Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Journal of the American College of Cardiology. 2006;47(1):91-7. DOI: 10.1016/j.jacc.2005.08.051
22. Karlstrom P, Alehagen U, Boman K, Dahlstrom U, on behalf of the UP-STEP-study group. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. European Journal of Heart Failure. 2011;13(10):1096-103. DOI: 10.1093/eurjhf/hfr078
23. LainchburyJG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure. Journal of the American College of Cardiology. 2009;55(1):53-60. DOI: 10.1016/j.jacc.2009.02.095
24. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure). European Journal of Heart Failure. 2010;12(12):1300-8. DOI: 10.1093/eurjhf/hfq169
25. Eurlings LWM, van Pol PEJ, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AHMM et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology. 2010;56(25):2090-100. DOI: 10.1016/j.jacc.2010.07.030
26. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM et al. The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic Peptide-Guided Therapy in Patients With Advanced Heart Failure. Journal of Cardiac Failure. 2011;17(8):613-21. DOI: 10.1016/j.cardfail.2011.04.012
27. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278-83. PMID: 12628948
28. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T et al. Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial). Journal ofthe American College of Cardiology. 2008;52(12):997-1003. DOI: 10.1016/j.jacc.2008.04.069
29. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clinical Biochemistry. 2010;43(9):714-9. DOI: 10.1016/j.clinbio-chem.2010.02.002
30. Dieplinger B, Januzzi JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — The PresageTM ST2 assay. Clinica Chimica Acta. 2009;409(1-2):33-40. DOI: 10.1016/j.cca.2009.08.010
31. Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. American Heart Journal. 2013;165(6):995-9. DOI: 10.1016/j.ahj.2013.02.029
32. Bayes-Genis A, Zamora E, de Antonio M, Galan A, VilaJ, Urrutia A et al. Soluble ST2 Serum Concentration and Renal Function in Heart Failure. Journal of Cardiac Failure. 2013;19(11):768-75. DOI: 10.1016/j.card-fail.2013.09.005
33. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL et al. Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. Clinical Chemistry. 2012;58(12):1673-81. DOI: 10.1373/clinchem.2012.192153
34. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdes Chavarri M et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Revista Espa-nola De Cardiologia. 2010;63(10):1171-8. PMID: 20875357